// App-Quantinova.ai

TPS11575 : Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.

Researchers

Presenter

  • Suzanne J. Forrest

Principal Investigators

  • Michael D. Kinnaman

  • J Andrew Livingston

  • Kieuhoa Tran Vo

  • Priscilla Merriam

  • Catherine Clinton

  • Kylene Desmith

  • Kerri Cavanaugh

  • Brunella Felicetti

  • Simon Smith

  • Emma Dean

  • Pei-Chi Kao

  • Wendy B. London

  • E. Alejandro Sweet-Cordero

  • Katherine A. Janeway

Medical Centers

  • Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorder Center, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of California, San Francisco, CA

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorder Center, Boston, MA

  • Early Oncology Clinical Science, R&D Oncology, AstraZeneca, Cambridge, United Kingdom

  • University of California, San Francisco, San Francisco, CA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Oncology (ONC)

Disease

  • Osteosarcoma

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT04417062

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved